Form 4: Medtronic EVP Marinaro's Latest Stock Transactions
Insider Transaction Report
Medtronic plc EVP Michael Marinaro reported routine transactions involving the acquisition and disposal of company ordinary shares, primarily related to RSU vesting and tax withholdings.
Summary
- Michael Marinaro, Executive Vice President and President of MedSurg and Americas at Medtronic plc, reported several transactions on August 1, 2025.
- Acquired 6,535 ordinary shares at a price of $0 upon the settlement of performance-vesting restricted stock units (RSUs) granted on August 1, 2022, including earned dividend equivalents.
- Disposed of 3,158 ordinary shares at $89.34, representing shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on August 1, 2025.
- Disposed of 1,741 ordinary shares at $89.34, representing shares withheld for payment of taxes upon the vesting of previously reported restricted stock units.
- Acquired 3,126 ordinary shares at $78 through the exercise of stock options.
- Disposed of 2,864 ordinary shares at $89.34, representing shares withheld for taxes related to the stock option exercise.
- Following these reported transactions, Michael Marinaro beneficially owns 52,991 ordinary shares directly.
Sentiment
Score: 6
Explanation: The filing reflects routine executive compensation activities, including the vesting of performance-based awards and option exercises, which are generally positive indicators of executive retention and reward for performance. The associated share disposals are for tax purposes, a standard practice, and do not indicate negative sentiment towards the company.
Positives
- Acquisition of 6,535 ordinary shares at $0 from the settlement of performance-vesting restricted stock units, indicating successful achievement of performance targets.
- Acquisition of 3,126 ordinary shares at $78 through stock option exercise, reflecting the executive's decision to convert options into shares.
Negatives
- Disposal of 3,158 ordinary shares at $89.34 for tax withholding upon RSU settlement.
- Disposal of 1,741 ordinary shares at $89.34 for tax payment upon RSU vesting.
- Disposal of 2,864 ordinary shares at $89.34 for tax withholding upon stock option exercise.
Future Outlook
The filing is a routine disclosure of insider stock transactions and does not contain forward-looking statements or guidance regarding Medtronic plc's future performance or strategic direction.
Industry Context
This Form 4 filing details routine equity compensation transactions for a senior executive at Medtronic plc, a leading medical technology company. Such filings are standard disclosures for publicly traded companies and reflect the typical compensation structures involving performance-based equity awards and stock options within the healthcare industry.
Stakeholder Impact
- Shareholders: The transactions represent a routine part of executive compensation, aligning executive interests with shareholder value through equity ownership. The net effect on outstanding shares is minimal.
- Employees: Reflects standard executive compensation practices, which may influence broader compensation strategies within the company.
Key Dates
| Date | Description |
|---|---|
| 08/01/2022 | Grant date of performance-vesting restricted stock units. |
| 08/03/2025 | Date stock options became exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. |
| 08/01/2025 | Date of all reported transactions, including RSU settlement, tax withholdings, and stock option exercise. |
| 08/04/2025 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Medtronic, MDT, SEC Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Stock Options, Michael Marinaro
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.